KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Total Current Liabilities (2017 - 2025)

Moderna (MRNA) has disclosed Total Current Liabilities for 7 consecutive years, with $2.2 billion as the latest value for Q4 2024.

  • On a quarterly basis, Total Current Liabilities fell 26.83% to $2.2 billion in Q4 2024 year-over-year; TTM through Dec 2024 was $2.2 billion, a 26.83% decrease, with the full-year FY2024 number at $2.2 billion, down 26.83% from a year prior.
  • Total Current Liabilities was $2.2 billion for Q4 2024 at Moderna, roughly flat from $2.2 billion in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $9.2 billion in Q1 2022 to a low of $134.6 million in Q1 2020.
  • A 5-year average of $4.1 billion and a median of $3.1 billion in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 107.97% in 2021, then tumbled 54.15% in 2023.
  • Moderna's Total Current Liabilities stood at $4.4 billion in 2020, then surged by 107.97% to $9.1 billion in 2021, then tumbled by 46.07% to $4.9 billion in 2022, then tumbled by 38.76% to $3.0 billion in 2023, then dropped by 26.83% to $2.2 billion in 2024.
  • Per Business Quant, the three most recent readings for MRNA's Total Current Liabilities are $2.2 billion (Q4 2024), $2.2 billion (Q3 2024), and $2.4 billion (Q2 2024).